Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Trading 12-11 14:15:09 EST

25.45

+1.89

+8.00%

High27.06	Low22.78	Vol4.58M
Open23.46	D1 Closing23.56	Amplitude18.17%
Mkt Cap4.46B	Tradable Cap1.70B	Total Shares175.28M
T/O117.02M	T/O Rate6.83%	Tradable Shares66.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":25.445,"timestamp":1765480506976,"preClose":23.56,"halted":0,"volume":4576263,"delay":0,"floatShares":66981036,"shares":175276526,"eps":-2.823734,"marketStatus":"Trading","change":1.885,"latestTime":"12-11 14:15:09 EST","open":23.46,"high":27.06,"low":22.78,"amount":117021451.6782,"amplitude":0.181664,"askPrice":25.47,"askSize":200,"bidPrice":25.44,"bidSize":480,"shortable":3,"etf":0,"ttmEps":-2.823734,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":23.56,"preHourTrading":{"tag":"盘前","latestPrice":23.74,"preClose":23.56,"latestTime":"09:28 EST","volume":24683,"amount":556887.355725,"timestamp":1765463301729},"postHourTrading":{"tag":"盘后","latestPrice":23.64,"preClose":23.56,"latestTime":"19:54 EST","volume":24599,"amount":579591.772,"timestamp":1765414462481},"volumeRatio":5.665649,"impliedVol":0.674,"impliedVolPercentile":0.788},"requestUrl":"/m/hq/s/IMVT","defaultTab":"news","newsList":[{"id":"2590545151","title":"Roivant Signals Major Pipeline Momentum With Accelerated Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545151","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545151?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:39","pubTimestamp":1765478340,"startTime":"0","endTime":"0","summary":"Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49344150/roivant-signals-major-pipeline-momentum-with-accelerated-timelines","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49344150/roivant-signals-major-pipeline-momentum-with-accelerated-timelines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4532","IMVT","BK4555","BK4585","BK4551","BK4501","NIU","BK4550","BK4187","BK4533","BK4588","BK4568","BK4558","DM","BK4516","BK4091","BK4546","ROIV","BK4161","LU0170899867.USD","BK4139","BK4534","MRNA","BK4548","GD","BK4007","BK4566"],"gpt_icon":0},{"id":"2590511175","title":"Roivant Sciences Fast-Tracks Key Drug Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511175","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511175?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:11","pubTimestamp":1765462310,"startTime":"0","endTime":"0","summary":"Roivant Sciences  said Thursday it has fast-tracked four of its key drug development programs.The new drug application filing for Brepocitinib in dermatomyositis is now expected early next year, with a commercial launch expected in early 2027. The company said its phase 3 trial for the drug candidate in non-infectious uveitis is fully enrolled, with topline data now expected in H2 2026.Meanwhile, the Brepocitinib proof-of-concept trial in cutaneous sarcoidosis is fully enrolled, with topline data expected in H1 2026.For the IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis, topline data are now expected next year, the company said.Roivant also said it led a funding round for Immunovant  that garnered gross proceeds of around $550 million. The funding will extend Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IMVT","BK4139","BK4007","BK4585","ROIV"],"gpt_icon":0},{"id":"2590051921","title":"Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday as Oracle Results Sour Investor Mood","url":"https://stock-news.laohu8.com/highlight/detail?id=2590051921","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590051921?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:54","pubTimestamp":1765461243,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.4% lower in Thursday's premarket activity, as Oracle's (ORCL) fis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IYJ","UNG","EQNR","SPY","EEM","VHT.AU","BITO",".IXIC","BETH","GEMI","XLP","IYE","AEO","IBB","XLI","RTH.AU","VIS","EETH","EQR","IYW","XLV","IYK","XLY","XRT","XLK","RTH","USO","IGM","BCO","SPY.AU",".DJI","IVV","ORCL","VHT","VDC","IPK","SOXX","XSD","IYH","FAS","FAZ","IMVT","XLF","XLE","EXI","IGV"],"gpt_icon":1},{"id":"2590562558","title":"Immunovant Inc - Offers 26.2 Mln Shares at $21.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590562558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590562558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 14:29","pubTimestamp":1765434566,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA2S3PWN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2590925562","title":"Press Release: Immunovant Announces Pricing of $550 Million Common Stock Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590925562","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590925562?lang=en_us&edition=fundamental","pubTime":"2025-12-11 14:29","pubTimestamp":1765434540,"startTime":"0","endTime":"0","summary":"-- Funding to provide runway through potential Graves' Disease commercial. Immunovant currently expects that its existing cash and cash equivalents, together with the proceeds from the transaction, will be sufficient to fund its operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 in the Graves' Disease indication.Immunovant offered 26.2 million shares of its common stock in the offering at an offering price of $21.00 per share. The offering is expected to close on or about December 12, 2025, subject to satisfaction of customary closing conditions.This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as \"can,\" \"may,\" \"might,\" \"will,\" \"would,\" \"should,\" \"expect,\" \"believe,\" \"estimate,\" \"design,\" \"plan,\" \"intend,\" and other similar expressions are intended to identify forward-looking","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","IMVT","BK4139"],"gpt_icon":0},{"id":"2586095280","title":"Immunovant (IMVT): Assessing Valuation Following R&D Leadership Restructuring and CMO Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=2586095280","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586095280?lang=en_us&edition=fundamental","pubTime":"2025-11-26 12:40","pubTimestamp":1764132000,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) announced that Michael Geffner, M.D., M.B.A., will no longer serve as Chief Medical Officer, following a restructuring of the company’s R&D leadership under CEO Eric Venker, M.D., PharmD. This move has prompted investors to consider what changes might be ahead for Immunovant’s strategy and outlook.\nSee our latest analysis for Immunovant.\nImmunovant’s recent R&D leadership shakeup comes amid a period of renewed market momentum, with a 30-day share price return of 26.45% and a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/immunovant-imvt-assessing-valuation-following-rd-leadership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/immunovant-imvt-assessing-valuation-following-rd-leadership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2585214667","title":"Immunovant Chief Medical Officer Michael Geffner Steps Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2585214667","media":"MT Newswires Live","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585214667?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:02","pubTimestamp":1763733770,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) said in a regulatory filing Friday that its Chief Medical Officer Michael Geffner has stepped down from his role, effective immediately.Geffner will offer certain consulting services","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","BK4139","IMVT"],"gpt_icon":0},{"id":"2585314396","title":"Immunovant Chief Medical Officer Michael Geffner Departs Amid R&D Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2585314396","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585314396?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:01","pubTimestamp":1763730063,"startTime":"0","endTime":"0","summary":"Immunovant Inc. has announced that Michael Geffner, M.D., M.B.A., will no longer serve as Chief Medical Officer effective November 21, 2025, as part of a restructuring of the company's R&D leadership under CEO Eric Venker, M.D., PharmD. Dr. Geffner will continue to provide consulting services to the company through April 30, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLblf0cS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IMVT","BK4139","BK4585"],"gpt_icon":0},{"id":"2585110032","title":"J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585110032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585110032?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:18","pubTimestamp":1763727491,"startTime":"0","endTime":"0","summary":"In a report released on November 19, Brian Cheng from J.P. Morgan maintained a Buy rating on Immunovant, with a price target of $34.00. The company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-immunovant-imvt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-immunovant-imvt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"gpt_icon":0},{"id":"2583680021","title":"H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680021?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:37","pubTimestamp":1763163476,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Immunovant today and set a price target of $35.00. According to TipRanks, Tsao is a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-immunovant-imvt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-immunovant-imvt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"gpt_icon":0},{"id":"2583590279","title":"Immunovant (IMVT): Assessing Valuation After Earnings Beat and Encouraging Graves’ Disease Study Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583590279","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583590279?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:27","pubTimestamp":1763044064,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) grabbed investor attention after releasing its latest earnings, reporting a quarterly loss per share that came in better than anticipated. At the same time, updates on key drug studies gave observers plenty to consider.\nSee our latest analysis for Immunovant.\nImmunovant’s 35.1% 1-month share price return stands out, particularly following positive clinical updates and a quarterly loss that beat expectations. Despite this short-term momentum, its total shareholder return over...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/immunovant-imvt-assessing-valuation-after-earnings-beat-and","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/immunovant-imvt-assessing-valuation-after-earnings-beat-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT"],"gpt_icon":0},{"id":"1111880053","title":"Stock Track | Immunovant Shares Plummet 8.01% on Q2 Earnings Miss and Clinical Trial Result Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=1111880053","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111880053?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:44","pubTimestamp":1762785867,"startTime":"0","endTime":"0","summary":"Shares of Immunovant, Inc. (IMVT) plummeted 8.01% in Monday's pre-market trading session following the release of its fiscal second-quarter financial results and updates on clinical trial timelines....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMVT"],"gpt_icon":0},{"id":"1165109008","title":"Stock Track | Immunovant Plummets 8.01% on Q2 Earnings Miss and Delayed Clinical Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1165109008","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165109008?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:44","pubTimestamp":1762785862,"startTime":"0","endTime":"0","summary":"Shares of Immunovant, Inc. (IMVT) plummeted 8.01% in pre-market trading on Monday following the release of its second-quarter financial results and clinical trial updates. The biopharmaceutical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMVT"],"gpt_icon":0},{"id":"2582587204","title":"Sector Update: Health Care Stocks Mixed Premarket Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2582587204","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582587204?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:17","pubTimestamp":1762784228,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Monday, with the Health Care Select Sector SPDR Fund (XLV) down 0.2% and the iShares Biotechnology ETF (IBB) 0.5% higher.Metsera (MTSR) announced late Friday an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT","NVO.AU","BK4585","BK7095","IE00B19Z3B42.SGD","RVTY","LU1894683348.USD","BK4592","BK7104","IE00BBT3K403.USD","XBI","BK4599","LU1894683264.USD","LU0306807586.USD","IE0002270589.USD","IE000M9KFDE8.USD","SG9999013999.USD","MTSR","BK4533","LU0321505439.SGD","BK4139","LU0058720904.USD","PFE","SG9999001176.USD","LU0321505868.SGD","NVO","LU1093756168.USD","BK4532","IBB","LU0289739699.SGD","LU0122379950.USD","IE00BZ1G4Q59.USD","SG9999011175.SGD","LU1066051498.USD","SG9999001176.SGD","LU0225284248.USD","LU0456855351.SGD","LU0868494617.USD","XLV","LU0234572021.USD","LU0985481810.HKD","LABU","IE00BKVL7J92.USD","BK4121","BK4534","BK4581","LU1057294990.SGD","PFE.AU","SG9999003800.SGD","LU1093756325.SGD"],"gpt_icon":1},{"id":"1135527889","title":"Stock Track | Immunovant Plunges 5.78% Pre-Market on Q2 Earnings Miss and Clinical Trial Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1135527889","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135527889?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:13","pubTimestamp":1762784016,"startTime":"0","endTime":"0","summary":"Shares of Immunovant, Inc. (IMVT) tumbled 5.78% in pre-market trading on Monday following the release of its second-quarter financial results and clinical trial updates. The biopharmaceutical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMVT"],"gpt_icon":0},{"id":"2582768138","title":"Immunovant Fiscal Q2 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2582768138","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582768138?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:32","pubTimestamp":1762777958,"startTime":"0","endTime":"0","summary":"Immunovant  reported a fiscal Q2 net loss Monday of $0.73 per diluted share, narrower than the net loss of $0.74 a year earlier.Analysts polled by FactSet expected a loss of $0.69.As of Sept. 30, the company said it had $521.9 million in cash and cash equivalents, which will likely finance operations through Graves' disease trial readout anticipated in 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","BK4585","IMVT"],"gpt_icon":0},{"id":"2582875506","title":"Autoimmune drugmaker Immunovant's Q2 net loss misses estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875506","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875506?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:19","pubTimestamp":1762777165,"startTime":"0","endTime":"0","summary":"Autoimmune drugmaker Immunovant's Q2 net loss misses estimatesOverviewImmunovant Q2 net loss misses analyst expectationsCompany advances IMVT-1402 trials across multiple indications, contributing to i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2582753958","title":"Earnings Flash (IMVT) Immunovant Posts Fiscal Q2 Loss $0.73 a Share, vs. FactSet Est of $0.70 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2582753958","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582753958?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:16","pubTimestamp":1762776980,"startTime":"0","endTime":"0","summary":"Earnings Flash (IMVT) Immunovant Posts Fiscal Q2 Loss $0.73 a Share, vs. FactSet Est of $0.70 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT"],"gpt_icon":0},{"id":"2582875586","title":"Biopharma Roivant's Q2 income from operations misses","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875586","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875586?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:14","pubTimestamp":1762776864,"startTime":"0","endTime":"0","summary":"Biopharma Roivant's Q2 income from operations missesOverviewRoivant Q2 revenue declines, missing analyst expectations for income from operationsCompany maintains strong cash position of $4.4 bln, supp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4585","IMVT","BK4139","BK4007","BK4588"],"gpt_icon":0},{"id":"2582873600","title":"Immunovant Q2 EPS $(0.73) Misses $(0.72) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873600","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873600?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:03","pubTimestamp":1762776200,"startTime":"0","endTime":"0","summary":"Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.72) by 0.69 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48748201/immunovant-q2-eps-0-73-misses-0-72-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USJW.SI","BK4139",".IXIC","BK4585","NQmain","NVIW.SI","BK4588","MNQmain","QID","QLD","TSYW.SI","USAW.SI","PSQ","SQQQ","IMVT","TQQQ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":0.0374},{"period":"1month","weight":0.0081},{"period":"3month","weight":0.4024},{"period":"6month","weight":0.5045},{"period":"1year","weight":-0.1859},{"period":"ytd","weight":-0.0488}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.099433},{"month":2,"riseRate":0,"avgChangeRate":-0.149849},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.062609},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.026413},{"month":5,"riseRate":0.333333,"avgChangeRate":0.069275},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.068981},{"month":7,"riseRate":0.571429,"avgChangeRate":0.040449},{"month":8,"riseRate":0.571429,"avgChangeRate":0.080342},{"month":9,"riseRate":0.857143,"avgChangeRate":0.12082},{"month":10,"riseRate":0.714286,"avgChangeRate":0.22916},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.571429,"avgChangeRate":0.121243}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}